Literature DB >> 21528848

Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).

Ryo Hayashi1, Kan Tanoue, Stewart R Durell, Deb K Chatterjee, Lisa M Miller Jenkins, Daniel H Appella, Ettore Appella.   

Abstract

PPM1D (PP2Cδ or Wip1) was identified as a wild-type p53-induced Ser/Thr phosphatase that accumulates after DNA damage and classified into the PP2C family. It dephosphorylates and inactivates several proteins critical for cellular stress responses, including p38 MAPK, p53, and ATM. Furthermore, PPM1D is amplified and/or overexpressed in a number of human cancers. Thus, inhibition of its activity could constitute an important new strategy for therapeutic intervention to halt the progression of several different cancers. Previously, we reported the development of a cyclic thioether peptide with low micromolar inhibitory activity toward PPM1D. Here, we describe important improvements in the inhibitory activity of this class of cyclic peptides and also present a binding model based upon the results. We found that specific interaction of an aromatic ring at the X1 position and negative charge at the X5 and X6 positions significantly increased the inhibitory activity of the cyclic peptide, with the optimized molecule having a K(i) of 110 nM. To the best of our knowledge, this represents the highest inhibitory activity reported for an inhibitor of PPM1D. We further developed an inhibitor selective for PPM1D over PPM1A with a K(i) of 2.9 μM. Optimization of the cyclic peptide and mutagenesis experiments suggest that a highly basic loop unique to PPM1D is related to substrate specificity. We propose a new model for the catalytic site of PPM1D and inhibition by the cyclic peptides that will be useful both for the subsequent design of PPM1D inhibitors and for identification of new substrates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21528848      PMCID: PMC3508689          DOI: 10.1021/bi101949t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  52 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

3.  Wip1 phosphatase modulates ATM-dependent signaling pathways.

Authors:  Sathyavageeswaran Shreeram; Oleg N Demidov; Weng Kee Hee; Hiroshi Yamaguchi; Nobuyuki Onishi; Calvina Kek; Oleg N Timofeev; Crissy Dudgeon; Albert J Fornace; Carl W Anderson; Yasuhiro Minami; Ettore Appella; Dmitry V Bulavin
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

Review 4.  Protein serine/threonine phosphatases: life, death, and sleeping.

Authors:  Monica Gallego; David M Virshup
Journal:  Curr Opin Cell Biol       Date:  2005-04       Impact factor: 8.382

5.  Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.

Authors:  Akinori Yoda; Xiao Zhou Xu; Nobuyuki Onishi; Kyoko Toyoshima; Hiroko Fujimoto; Naoko Kato; Isao Oishi; Takeshi Kondo; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

6.  Insights into the catalytic mechanism of PPM Ser/Thr phosphatases from the atomic resolution structures of a mycobacterial enzyme.

Authors:  Marco Bellinzoni; Annemarie Wehenkel; William Shepard; Pedro M Alzari
Journal:  Structure       Date:  2007-07       Impact factor: 5.006

7.  PPM1D is a potential target for 17q gain in neuroblastoma.

Authors:  Fumiko Saito-Ohara; Issei Imoto; Jun Inoue; Hajime Hosoi; Akira Nakagawara; Tohru Sugimoto; Johji Inazawa
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

8.  Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components.

Authors:  A Ehrbrecht; U Müller; M Wolter; A Hoischen; A Koch; B Radlwimmer; B Actor; A Mincheva; T Pietsch; P Lichter; G Reifenberger; R G Weber
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

Review 9.  Wip1-deficient mice are resistant to common cancer genes.

Authors:  Martin Harrison; Jing Li; Yan Degenhardt; Timothy Hoey; Scott Powers
Journal:  Trends Mol Med       Date:  2004-08       Impact factor: 11.951

10.  A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Authors:  S Rayter; R Elliott; J Travers; M G Rowlands; T B Richardson; K Boxall; K Jones; S Linardopoulos; P Workman; W Aherne; C J Lord; A Ashworth
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

View more
  13 in total

1.  Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.

Authors:  Aidan G Gilmartin; Thomas H Faitg; Mark Richter; Arthur Groy; Mark A Seefeld; Michael G Darcy; Xin Peng; Kelly Federowicz; Jingsong Yang; Shu-Yun Zhang; Elisabeth Minthorn; Jon-Paul Jaworski; Michael Schaber; Stan Martens; Dean E McNulty; Robert H Sinnamon; Hong Zhang; Robert B Kirkpatrick; Neysa Nevins; Guanglei Cui; Beth Pietrak; Elsie Diaz; Amber Jones; Martin Brandt; Benjamin Schwartz; Dirk A Heerding; Rakesh Kumar
Journal:  Nat Chem Biol       Date:  2014-01-05       Impact factor: 15.040

2.  Binding of a third metal ion by the human phosphatases PP2Cα and Wip1 is required for phosphatase activity.

Authors:  Kan Tanoue; Lisa M Miller Jenkins; Stewart R Durell; Subrata Debnath; Hiroyasu Sakai; Harichandra D Tagad; Kazushige Ishida; Ettore Appella; Sharlyn J Mazur
Journal:  Biochemistry       Date:  2013-08-16       Impact factor: 3.162

3.  Discovery of Novel Small-Molecule Scaffolds for the Inhibition and Activation of WIP1 Phosphatase from a RapidFire Mass Spectrometry High-Throughput Screen.

Authors:  Victor Clausse; Yuhong Fang; Dingyin Tao; Harichandra D Tagad; Hongmao Sun; Yuhong Wang; Surendra Karavadhi; Kelly Lane; Zhen-Dan Shi; Olga Vasalatiy; Christopher A LeClair; Rebecca Eells; Min Shen; Samarjit Patnaik; Ettore Appella; Nathan P Coussens; Matthew D Hall; Daniel H Appella
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-28

4.  Structurally diverse low molecular weight activators of the mammalian pre-mRNA 3' cleavage reaction.

Authors:  Min Ting Liu; Nagaraja N Nagre; Kevin Ryan
Journal:  Bioorg Med Chem       Date:  2013-12-15       Impact factor: 3.641

5.  Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.

Authors:  Harichandra D Tagad; Subrata Debnath; Victor Clausse; Mrinmoy Saha; Sharlyn J Mazur; Ettore Appella; Daniel H Appella
Journal:  ChemMedChem       Date:  2018-04-06       Impact factor: 3.466

6.  The role of PPM1D in cancer and advances in studies of its inhibitors.

Authors:  Wenhong Deng; Jieqing Li; Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao; Zhaoxia Gao; Jay Vadgama; Yong Wu
Journal:  Biomed Pharmacother       Date:  2020-01-29       Impact factor: 7.419

7.  WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C.

Authors:  Ya-ling Tang; Xin Liu; Shi-yu Gao; Hao Feng; Ya-ping Jiang; Sha-sha Wang; Jing Yang; Jian Jiang; Xiang-rui Ma; Ya-jie Tang; Yu Chen; Xin-hua Liang
Journal:  Oncotarget       Date:  2015-04-20

Review 8.  Cyclic peptides as therapeutic agents and biochemical tools.

Authors:  Sang Hoon Joo
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

9.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

Authors:  Elise Ruark; Katie Snape; Peter Humburg; Chey Loveday; Ilirjana Bajrami; Rachel Brough; Daniel Nava Rodrigues; Anthony Renwick; Sheila Seal; Emma Ramsay; Silvana Del Vecchio Duarte; Manuel A Rivas; Margaret Warren-Perry; Anna Zachariou; Adriana Campion-Flora; Sandra Hanks; Anne Murray; Naser Ansari Pour; Jenny Douglas; Lorna Gregory; Andrew Rimmer; Neil M Walker; Tsun-Po Yang; Julian W Adlard; Julian Barwell; Jonathan Berg; Angela F Brady; Carole Brewer; Glen Brice; Cyril Chapman; Jackie Cook; Rosemarie Davidson; Alan Donaldson; Fiona Douglas; Diana Eccles; D Gareth Evans; Lynn Greenhalgh; Alex Henderson; Louise Izatt; Ajith Kumar; Fiona Lalloo; Zosia Miedzybrodzka; Patrick J Morrison; Joan Paterson; Mary Porteous; Mark T Rogers; Susan Shanley; Lisa Walker; Martin Gore; Richard Houlston; Matthew A Brown; Mark J Caufield; Panagiotis Deloukas; Mark I McCarthy; John A Todd; Clare Turnbull; Jorge S Reis-Filho; Alan Ashworth; Antonis C Antoniou; Christopher J Lord; Peter Donnelly; Nazneen Rahman
Journal:  Nature       Date:  2012-12-16       Impact factor: 49.962

10.  Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis.

Authors:  Linda Zane; Junichiro Yasunaga; Yu Mitagami; Venkat Yedavalli; Sai-Wen Tang; Chia-Yen Chen; Lee Ratner; Xiongbin Lu; Kuan-Teh Jeang
Journal:  Retrovirology       Date:  2012-12-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.